New Developing Treatments for Molluscum Contagiosum.

Article Details

Citation
Copy to clipboard

Lacarrubba F, Micali G, Trecarichi AC, Quattrocchi E, Monfrecola G, Verzi AE

New Developing Treatments for Molluscum Contagiosum.

Dermatol Ther (Heidelb). 2022 Dec;12(12):2669-2678. doi: 10.1007/s13555-022-00826-7. Epub 2022 Oct 14.

PubMed ID
36239905 [ View in PubMed
]
Abstract

A large variety of treatments for molluscum contagiosum (MC) are available, but none are Food and Drug Administration (FDA) approved and there is no consensus on the optimal approach, mainly owing to a lack of high-level data. Physical modalities are widely used, but require repeated outpatient visits for administration, are painful and difficult to perform in children, and are associated with the possibility of residual scarring and post-inflammatory hypo- or hyperpigmentation. Two experimental topical drugs, a new standardized preparation of topical cantharidin, called VP-102, and a topical nitric oxide (NO)-releasing product containing berdazimer, called SB206, represent promising products that have been designed to overcome the limitations of current treatments. They have recently shown good results in terms of safety and efficacy in large cohorts of patients in phase III studies and have the potential to be the first FDA-approved therapies for the treatment of MC.

DrugBank Data that Cites this Article

Drugs